CD8A and progressive multifocal leukoencephalopathy: The immune checkpoint inhibitors pembrolizumab and nivolumab have been investigated based on the observation that the expression of programmed cell death protein 1 is elevated in blood and CSF CD4+ and CD8+ T cells in patients with PML.18,19,51, –53 Mixed results have been reported.